• Osteopore signed exclusive distribution deal with Zimmer Biomet in 2024
• Zimmer Biomet launched Osteopore products in Europe, Australia, and Hong Kong
• Osteopore implant sales in these regions grew 3-fold in first 12 months

Australian-Singaporean regenerative medicine company Osteopore Limited (ASX: OSX) has provided a business progress update on its Exclusive Distribution Agreement with global medical technology leader Zimmer Biomet (NYSE and SIX:ZBH). Osteopore struck the agreement with Zimmer Biomet on 16 July 2024 to distribute Osteopore's craniofacial products in Europe, the Middle East, Africa (EMEA), and Asia Pacific (APAC) including Australia and New Zealand. In the first 12 months of the partnership, from 2024 H2 to 2025 H1, Zimmer Biomet has launched Osteopore products in Europe, Australia, and Hong Kong. The number of Osteopore craniofacial products sold in these regions and countries grew three-fold compared to the previous 12-month period (2023 H2 to 2024 H1) prior to Zimmer Biomet's appointment. Osteopore CEO Dr Yujing Lim commented on the strong and encouraging performance, and also highlighted the company's resilience in manufacturing capacity and ability to scale. Looking ahead, with the recent European approval of Osteopore's custom-made cranioplasty implants, the company expects stronger traction gradually from existing markets and will work with Zimmer Biomet to launch new markets.

Looking ahead, with the recent European approval of Osteopore's custom-made cranioplasty implants, the company expects stronger traction gradually from existing markets and will work with Zimmer Biomet to launch new markets.